Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Wet AMD: full-pipeline trial registry
4 of 5 indexed Wet AMD trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Wet AMD: 5 US clinical trials tracked, 4 recruiting.
Wet AMD is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Adverum Biotechnologies, running 2 of these trials.
Enrollment posture brief
Registry condition wet-amd
OPEN 4 | RECR 80% | LATE 3 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Wet AMD lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Wet AMD on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Wet AMD is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Wet AMD research.
Adverum Biotechnologies accounts for 2 of 5 trials (40%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Wet AMD enrolment sits around 284 participants.
Median target enrolment is 284 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
Wet AMD research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
AbbVie
NCT05407636
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
AbbVie
NCT04704921
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies
NCT07482176
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Adverum Biotechnologies
NCT06856577
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
NexThera Co.
NCT06704009
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Wet AMD records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Wet AMD trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Wet AMD page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Wet AMD trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Adverum Biotechnologies sponsors the most Wet AMD trials on record, review their full trial history before evaluating a specific study. See Adverum Biotechnologies's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Wet AMD condition card totals 5 registered trials; most-linked intervention Aflibercept; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.